# EDGAR Filing Document

**Accession Number:** 0001100397
**File Stem:** 0001493152-23-002246
**Filing Date:** 2023-1
**Character Count:** 7873
**Document Hash:** 2c16e6df5e2690d60645f99ab62b3244
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002246.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001493152-23-002246

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230119

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** SIDRANSKY DAVID
- **CENTRAL INDEX KEY:** 0001277161

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36138
- **FILM NUMBER:** 23545488

**MAIL ADDRESS:**
- **STREET 1:** JOHNS HOPKINS UNIVERSITY
- **STREET 2:** 720 RUTLAND AVENUE
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21205
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ayala Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001100397
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 841521955
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**BUSINESS ADDRESS:**
- **STREET 1:** 9 DEER PARK DRIVE
- **STREET 2:** SUITE K-1
- **CITY:** MONMOUTH JUNCTION
- **STATE:** NJ
- **ZIP:** 08852
- **BUSINESS PHONE:** 732 545 1590

**MAIL ADDRESS:**
- **STREET 1:** 9 DEER PARK DRIVE
- **STREET 2:** SUITE K-1
- **CITY:** MONMOUTH JUNCTION
- **STATE:** NJ
- **ZIP:** 08852

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Advaxis, Inc.
- **DATE OF NAME CHANGE:** 20050105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GREAT EXPECTATIONS & ASSOCIATES INC
- **DATE OF NAME CHANGE:** 19991203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>SIDRANSKY DAVID<br><sub>(Last) (First) (Middle)</sub><br>9 DEER PARK DRIVE, SUITE K-1<br><sub>(Street)</sub><br>MONMOUTH JUNCTION, NJ 08852<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-19 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ayala Pharmaceuticals, Inc. [ ADXS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-19 |  | A |  | 46 | A | <sup>(1)</sup> | 46 | I | Held by Reporting Person's Son |
| Common Stock |  |  |  |  |  |  |  | 93 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $55.23 | 2023-01-19 |  | A |  | 2342 |  | <sup>(2)</sup> | 2031-06-09 | Common Stock | 2342 | <sup>(3)</sup> | 2342 | D |  |
| Stock Option | $8.70 | 2023-01-19 |  | A |  | 2342 |  | <sup>(4)</sup> | 2032-06-12 | Common Stock | 2342 | <sup>(5)</sup> | 2342 | D |  |
| Stock Option | $16128 |  |  |  |  |  |  | <sup>(2)</sup> | 2025-05-27 | Common Stock | 17 |  | 17 | D |  |
| Stock Option | $15372 |  |  |  |  |  |  | <sup>(2)</sup> | 2025-11-04 | Common Stock | 42 |  | 42 | D |  |
| Stock Option | $9252 |  |  |  |  |  |  | <sup>(2)</sup> | 2026-11-03 | Common Stock | 25 |  | 25 | D |  |
| Stock Option | $3828 |  |  |  |  |  |  | <sup>(2)</sup> | 2027-11-01 | Common Stock | 25 |  | 25 | D |  |
| Stock Option | $648 |  |  |  |  |  |  | <sup>(2)</sup> | 2028-11-04 | Common Stock | 25 |  | 25 | D |  |
| Stock Option | $24.80 |  |  |  |  |  |  | <sup>(2)</sup> | 2029-10-23 | Common Stock | 125 |  | 125 | D |  |
| Stock Option | $52.80 |  |  |  |  |  |  | <sup>(6)</sup> | 2030-05-03 | Common Stock | 163 |  | 163 | D |  |

---

### Footnotes:

(1) Received in exchange for 250 shares of the common stock of Ayala Pharmaceuticals, Inc. ("Old Ayala") in the merger of Old Ayala into the Issuer (the "Merger"). On the day prior to the effective date of the Merger, the closing price of Old Ayala's common stock was $0.53 per share, and the closing price of the Issuer's common stock was $2.95 per share.

(2) This option is fully vested and exercisable.

(3) Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $10.35 per share.

(4) This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

(5) Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $1.63 per share.

(6) Two-thirds of this award is currently vested and the remaining one-third will be vested on May 4, 2023.

**Signature:** /s/ David Sidransky  
**Date:** 2023-01-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**